The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) had its target price upped by The Goldman Sachs Group from $29.00 to $33.00 in a research note published on Friday morning, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company's stock.

AGIO has been the topic of several other research reports. Royal Bank of Canada dropped their price objective on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform rating on the stock in a research note on Friday, February 16th. JPMorgan Chase & Co. decreased their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a neutral rating for the company in a research report on Friday, February 23rd. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $34.75.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded down $0.04 during trading hours on Friday, hitting $34.54. The company had a trading volume of 807,884 shares, compared to its average volume of 800,345. The firm has a market capitalization of $1.96 billion, a P/E ratio of -5.44 and a beta of 0.81. The firm's fifty day moving average is $30.58 and its 200-day moving average is $25.55. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $35.50.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.64) by $0.19. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. The company's revenue for the quarter was up 46.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.47) EPS. Analysts anticipate that Agios Pharmaceuticals will post -5.29 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider James William Burns sold 2,642 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the sale, the insider now owns 34,518 shares of the company's stock, valued at approximately $1,124,251.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Brian Goff sold 4,156 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the transaction, the chief executive officer now owns 53,780 shares in the company, valued at approximately $1,751,614.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider James William Burns sold 2,642 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares of the company's stock, valued at approximately $1,124,251.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,035 shares of company stock valued at $475,277. Insiders own 4.24% of the company's stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AGIO. China Universal Asset Management Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 96.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 700 shares during the period. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth $41,000. NEOS Investment Management LLC bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at $210,000. Headlands Technologies LLC raised its stake in shares of Agios Pharmaceuticals by 31.3% in the 3rd quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 2,153 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agios Pharmaceuticals by 9.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company's stock worth $255,000 after acquiring an additional 942 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.